Where is RegCell located?

RegCell is headquartered in Fujisawa, Japan.

Who is the current CEO of RegCell?

Noriko Sakaguchi and Naoto Matsuda s of RegCell.

Is RegCell a funded company?

RegCell is a funded company, having raised a total of $7M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of RegCell?

RegCell's latest funding was a $***** Series A round on May 10, 2017, with participation from 1 investor.

Where does RegCell rank among its competitors?

RegCell ranks 330th amongst 683 active competitors, of which 256 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of RegCell?

RegCell's top competitors include BeiGene, Biogen and argenx. Among them, Immuneel secured the most recent funding round in June, 2026.

RegCell - 2026 Company Profile, Team, Funding & Competitors

Company Details

RegCell is developing regulatory T cells based therapies for the treatment of Autoimmune diseases. The company research protocol involves regulating control T cells to proliferate and activate them outside the body and then return them to patients. The company has early stage preclinical stage programs for rheumatism and acute immune rejection after organ transplantation.

Key Metrics

Founded Year

2016

Location

Fujisawa, Japan

Stage

Series A

Total Funding

$7M in 2 rounds

Latest Funding Round

Series A, May 10, 2017, $*****

Investors

Fujifilm & 2 more

Ranked

330^th among 683 active competitors

Similar Companies

BeiGene & 791 more

View RegCell's full profile

RegCell has raised a total funding of $7M over 2 rounds. Its latest funding round was a Series A round on May 10, 2017 for $*****. 1 investor participated in its latest round. RegCell has 3 institutional investors.

Here is the list of recent funding rounds of RegCell:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 10, 2017	2526469	Series A	1029201	8195429	3936976	1592403

Access funding benchmarks and valuations. Sign up today!

View details of RegCell's funding rounds and investors

The founders of RegCell is Shimon Sakaguchi. Naoto Matsuda and Noriko Sakaguchi are the CEOs of RegCell.

Here are the details of RegCell's key team members:

Shimon Sakaguchi: Founder of RegCell.
Noriko Sakaguchi: Co-CEO of RegCell.
Contact Info: 1 email address
Naoto Matsuda: Co-CEO of RegCell.

View details of RegCell's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RegCell include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of RegCell, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	75/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	74/100
5th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
7th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
8th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	BlackRock, RA Capital Management & 9 others	70/100
9th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
10th	ImmunoACT 2018, Mumbai (India), Series B	Developer of cell and gene therapies for cancer treatment	$15.9M	SINE, Laurus Labs & 4 others	69/100
330th	RegCell 2016, Fujisawa (Japan), Series A	Regulatory T cells based therapies for the treatment of autoimmune diseases	$7M	Fujifilm, Nissay Capital & 1 others	36/100